Snow R W, Marsh K
The Wellcome Trust/Kenya Medical Research Institute Collaborative Programme, P.O. Box 43640, Nairobi ; Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DS (UK).
Bull Inst Pasteur. 1998 Mar;96(1):15-23. doi: 10.1016/S0020-2452(98)80025-0.
There is a resurgence of interest in the clinical epidemiology of malaria among African children. This renewed interest follows fifty years of failure to eradicate infection in Africa and redirected efforts toward disease control and prevention. We have a poor understanding of the mechanisms by which clinical immunity is acquired; however, several recent studies have provided new insights into how fast clinical protection is acquired under the varied transmission intensities common to Africa. What is clear is that the frequency with which individuals encounter infection from birth will determine the speed with which they become clinically immune and the patterns of severe pathology they are likely to experience. There remains doubt and concerns over the long-term consequences of reducing natural parasite exposure in several areas of Africa. New field studies are urgently required to tackle these issues so that control may be guided by an improved understanding of malaria as a disease that can lead to death.
非洲儿童疟疾临床流行病学再度引起人们的关注。这种新的关注源于五十年来在非洲根除感染的努力失败,转而将精力重新投向疾病控制和预防。我们对获得临床免疫力的机制了解甚少;然而,最近的几项研究为在非洲常见的不同传播强度下多快能获得临床保护提供了新的见解。很明显,个体从出生起接触感染的频率将决定他们获得临床免疫的速度以及可能经历的严重病理模式。在非洲几个地区,减少自然寄生虫暴露的长期后果仍存在疑问和担忧。迫切需要开展新的实地研究来解决这些问题,以便在对疟疾这种可能导致死亡的疾病有更好理解的指导下进行防控。